IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Company offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.
Manufacturing
Pharmaceutical Products
$5.12B
26.3K
NEW YORK, New York
Raimon G. Roura
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = GRFS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GRFS Grifols SA | 68 | 83 | 96 | 50 | - | 1.6x | 14.5% | 4.0% | 38.8% | 16.6% | 3.0% | 1.5% | 0.0% | 0.0x | $5.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Grifols SA (GRFS) receives a "Buy" rating with a composite score of 68.0/100. It ranks #153 out of 7,333 stocks in our coverage universe and carries a 4-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Raimon G. Roura
Chief Executive Officer
Labor Force
26,300
83
75
82
Audit Verdict: High quality, disciplined capital allocation, and low volatility suggest strong governance.
No recent insider transactions available for GRFS
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Conservative, efficient capex — capital discipline signals management quality
Top-rated overall — multiple factors aligned for strong entry
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GRFS.
View All RatingsYOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Conservative accounting — High cash conversion efficiency
Material decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 83 | 94 | -11DRAG |
| MOMENTUM | 50 | 37 | +13ALPHA |
| VALUATION | 96 | 98 | -2NEUTRAL |
| INVESTMENT | 75 | 100 | -25DRAG |
| STABILITY | 82 | 84 | -2NEUTRAL |
| SHORT INT | 23 | 7 | +16ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 14.5% (sector -2.5%)
GM 39% vs sector 43%, OM 17% vs sector 1%
Capital turnover N/A, R&D intensity 5.3%
Rev growth 1%, 8yr history
Interest coverage N/A, Net debt/EBITDA -1.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Grifols SA receives a Buy rating with a composite score of 68.0/100 and 4 out of 5 stars, ranking #153 of 7,333 stocks in our universe. GRFS displays a favorable combination of factors that positions it above the majority of the market. While not without risk, the quantitative profile supports a constructive outlook.
GRFS earns a quality score of 83/100, indicating above-average business quality. The company reports a return on equity of 14.5% (sector avg: -2.5%), gross margins of 38.8% (sector avg: 42.5%), net margins of 3.0% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
From a valuation perspective, GRFS scores an exceptional 96/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include an EV/EBITDA of 1.55x, a P/B ratio of 1.05x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
GRFS shows a solid investment score of 75/100, reflecting measured but productive capital allocation. Key growth metrics include revenue growth of 1.5% vs. a sector average of 5.9% and a return on assets of 4.0% (sector: -0.1%). This suggests the company is investing at an appropriate level to sustain growth without overextending its balance sheet.
GRFS demonstrates moderate momentum with a score of 50/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 1.5% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
GRFS shows good financial stability with a score of 82/100. Key stability metrics include a beta of 0.87 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
Grifols SA's short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. At $5.1B (mid-cap), GRFS carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Grifols SA is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #153 of 7,333 overall (98th percentile). Key comparisons include ROE of 14.5% exceeding the -2.5% sector median and operating margins of 16.6% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
Quant Factor Profile
Key factor gap
Value (96) vs Short Int. (23) — closing this gap could shift the rating.
EV/EBITDA 86% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 683% BELOW SECTOR MEDIAN
Gross Margin 9% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate Grifols SA (GRFS) as a Buy with a composite score of 68.0/100 at a current price of $9.06. The stock scores above average across the majority of our six quantitative factors and ranks #153 out of 7,333 stocks in our universe, reflecting a favorable risk-reward profile.
The rating is primarily driven by strength in value (96th percentile) and quality (83th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a Narrow Moat rating (40/100), Low uncertainty, and Standard capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Grifols SA holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 68.0/100 places it at rank #153 in our full 7,333-stock universe. At $5.1B in market capitalization, Grifols SA is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 1%, though momentum at the 50th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 39% (-3.7pp vs sector) narrow to operating margins of 17% (+15.3pp vs sector) and net margins of 3.0%, yielding a gross-to-net conversion rate of 8%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $9.06, Grifols SA appears undervalued relative to its fundamentals. Our value factor score of 96/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at EV/EBITDA of 1.6x (discounted to peers), P/B of 1.1x, P/S of 0.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock's Buy rating (composite score 68.0/100) reflects broad-based quantitative strength, placing it in the top 20% of our 7,333-stock universe.
A value factor score of 96/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
A conservative balance sheet (0% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Thin net margins of 3.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Low uncertainty rating to Grifols SA. The company exhibits strong financial stability with a beta of 0.87, conservative leverage (0% D/E), and a stability factor in the 82th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
We identify no major risk factors at this time. The company's stability factor sits at the 82th percentile with quality at the 83th percentile, both of which support our low-risk assessment. The absence of material leverage, profitability, or volatility concerns reduces the likelihood of a permanent capital loss scenario.
Key risk mitigants include: conservative leverage (0% D/E) limits balance sheet risk; above-average stability (82th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Grifols SA's capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 14.5%, and the balance sheet is managed within acceptable parameters (D/E: 0%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; Grifols SA falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, Grifols SA receives a Buy rating with a composite score of 68.0/100 (rank #153 of 7,333). Our quantitative framework assigns a Narrow Moat (40/100, trend: stable), Low uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 77/100.
Our analysis supports a constructive view on Grifols SA. The combination of identifiable competitive advantages, low uncertainty, and standard capital allocation creates a risk-reward profile that favors accumulation at current levels. We recommend investors consider adding this name to portfolios aligned with the stock's risk profile.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Grifols SA a Narrow Moat rating with a composite moat score of 40/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Grifols SA can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 14.5/20.
The strongest moat sources are margin superiority (14.5/20) and financial resilience (9.8/20). GM 39% vs sector 43%, OM 17% vs sector 1%. Interest coverage N/A, Net debt/EBITDA -1.2x. These pillars form the core of Grifols SA's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (1.9/20) and economic value creation (6.7/20). Capital turnover N/A, R&D intensity 5.3%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Grifols SA's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 39% providing a solid profitability foundation, operating margins of 17% reflecting effective cost management. The margin cascade from 39% gross to 17% operating to 3.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 83th percentile.
The margin profile shows gross margins of 39%, operating margins of 17%, net margins of 3.0%. Return metrics include ROE of 14.5% and ROA of 4.0%. Relative to the Manufacturing sector, gross margins are 3.7 percentage points below the sector median of 43%, and ROE of 14.5% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 0%, revenue growth of 1%. The sector median D/E is 0%, putting Grifols SA in a relatively stronger balance sheet position. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
European equities traded in the US as American depositary receipts were trending lower late Thursday
European equities traded in the US as American depositary receipts were marginally lower late Tuesda
Insightful Analysis of Brandes Investment Partners, LP (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing
The global intravenous solutions market is projected to grow at a CAGR of 8.0% from 2024 to 2031, driven by the increasing elderly population, rising rates of chronic diseases, and advancements in medical technology.